medigraphic.com

2017, Número 4

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2017; 84 (4)


Quimioprofilaxis para cáncer de ovario

Vargas-Aguilar VM, Arroyo-Álvarez K

Idioma: Ingles.
Referencias bibliográficas: 42
Paginas: 212-216
Archivo PDF: 168.30 Kb.


RESUMEN

El cáncer de ovario representa la neoplasia con mayor mortalidad en el mundo, la neoplasia epitelial es la más frecuente entre ellos. Los tratamientos antineoplásicos han contribuido poco en incrementar la sobrevida de los pacientes; sin embargo, el tamizaje no ha disminuido la mortalidad. Pacientes con trastornos genéticos hereditarios como BRCA1 y 2, síndrome de Lynch tienen predisposición de presentar cáncer de ovario, por lo que la salpingooforectomía bilateral es una alternativa preventiva. Los anticonceptivos orales combinados son una alternativa de prevención para cáncer de ovario, especialmente en aquéllos que aún no completan paridad, los meta-análisis demuestran que el uso de anticonceptivos orales en edad temprana generan protección hasta por 20 años posterior a suspenderlos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30.

  3. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumors of female reproductive organs 2014 IARC.

  4. Kurman RJ, Shih IeM. The dualistic model of ovariam carcinogenesis: revised, and expanded. Am J Pathol 2016; 186(4): 733-47.

  5. Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol 2016; 35(5): 430-41.

  6. CRUK, Ovarian Cancer, Key Stats, Cancer Statistics, Nov 2014 ed. CRUK: Cancer Research UK 2014, pp. 1-2 (http://publications.cancerresearchuk.org/downloads/Product/CS_KF_OVARY.pdf)

  7. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011; 305(22): 2295-303.

  8. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013; 121(4): 709-16.

  9. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101(2): 80-7.

  10. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305(22): 2304-10.

  11. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006; 144(6): 397-406.

  12. SEER, SEER Cancer Statistics Factsheets: Ovary Cancer, National Cancer Institute, Bethesda, MD, USA, 2014 (http://seer.cancer.gov/statfacts/html/ovary.html) (accessed 10/03/2015).

  13. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015; 47(2): 164-71.

  14. Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet 2015; 57(7): 465-75.

  15. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302(5645): 643-46.

  16. Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clark L, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012; 30(5): 497-506.

  17. Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17(1): 55-67.

  18. Chiaffarino F, Parazzini F, Decarli A, Franceschi S, Talamini R, Montella M, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005; 97(2): 318-22.

  19. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993; 270(23): 2813-8.

  20. Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10(5): 296-306.

  21. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371(9609): 303-14.

  22. Havrilesky LJ, Sanders GD, Kulasingam S, Chino JP, Berchuck A, Marks JR, et al. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: Implications for potential mortality reduction. Cancer 2011; 117(3): 545-53.

  23. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22(7): 1315-27.

  24. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo-Urrutia R, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; (212): 1-514.

  25. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335(7621): 651.

  26. Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talami R, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001; 12(3): 337-41.

  27. Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008; 122(7): 1598-603.

  28. Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E, Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Br J Cancer 2004; 90(7): 1386-91.

  29. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 2008; 19(2): 237-43.

  30. Mills PK, Riordan DG, Cress RD. Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. Gynecol Oncol 2004; 95(1): 215-25.

  31. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller F, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4): 235-40.

  32. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid hormones and reproductions. Am J Epidemiol 2000; 152(3): 233-41.

  33. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83(3): 575-85.

  34. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control 2009; 20(1): 27-34.

  35. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001; 95(6): 370-4.

  36. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000; 11(2): 106-10.

  37. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158(7): 629-38.

  38. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166(8): 894-901.

  39. Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012; 119(6): 672-7.

  40. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer 2012; 131(4): 938-48.

  41. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008; 167(9): 1059-69.

  42. Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC. . Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001; 153(9): 860-4.




2020     |     www.medigraphic.com